A Study of Purified Human Antibodies Administered Subcutaneously to Patients With Multifocal Motor Neuropathy (MMN)

Inclusion Criteria: * Patients with documented clinical diagnosis and electrophysiological evidence of MMN * Patients who have previously responded to intravenous immunoglobulin (IVIG) and have been on stable treatment with IVIG for at least 12 weeks prior to screening * Patients treated with the equivalent of ≥0.4g/kg body weight (bw) IVIG per month * Provision of informed consent by patient Exclusion Criteria: * Aspartate aminotransferase (ASAT) or alanine aminotransferase (ALAT) concentration \>2.5 times the upper normal limit (UNL) * Creatinine concentration \>1.5 times the UNL * Known allergic reactions to blood products * Any skin disease interfering with the assessment of injection site reactions * Any other medical condition, which in the opinion of the investigator, might interfere with successful completion of the protocol * Any condition likely to interfere with the evaluation of the study drug or satisfactory conduct of the trial * Participation in a study with an investigational drug within three months prior to enrolment * Patients treated with the equivalent of \>2.0g/kg bw IVIG per month